{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:49:46Z","timestamp":1789915786291,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019886","name":"Legend Biotech USA Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019886","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clml.2025.08.005","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T16:04:45Z","timestamp":1754582685000},"page":"85-93","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Optimizing Selection of Bridging Therapies Prior to CAR-T Therapy Administration for Multiple Myeloma: Clinical Pearls From an Expert Roundtable"],"prefix":"10.1016","volume":"26","author":[{"given":"Sikander","family":"Ailawadhi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Larry D.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binod","family":"Dhakal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-3578","authenticated-orcid":false,"given":"Doris K.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.08.005_bib0001","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2025.08.005_bib0002","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.08.005_bib0003","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1016\/j.clml.2024.01.014","article-title":"Optimizing the CAR T-cell therapy experience in multiple myeloma: clinical pearls from an expert roundtable","volume":"24","author":"Ailawadhi","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.08.005_bib0004","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/bjh.19227","article-title":"Bridging treatment prior to chimeric antigen receptor T-cell therapy in multiple myeloma","volume":"204","author":"Bal","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2025.08.005_bib0005","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2025.08.005_bib0006","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2025.08.005_bib0007","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(24)00094-9","volume":"25","author":"Lin","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2025.08.005_bib0008","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41408-024-00993-0","article-title":"Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium","volume":"14","author":"Afrough","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2025.08.005_bib0009","first-page":"17","article-title":"Chimeric antigen receptor T cell therapy for myeloma: where are we now and what is needed to move chimeric antigen receptor T cells forward to earlier lines of therapy? Expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"30","author":"Jr","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2025.08.005_bib0010","series-title":"The EBMT\/EHA CAR-T Cell Handbook","first-page":"127","article-title":"Bridging chemotherapy: multiple myeloma","author":"Manier","year":"2022"},{"key":"10.1016\/j.clml.2025.08.005_bib0011","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2025.08.005_bib0012","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2025.08.005_bib0013","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S2152-2650(24)01908-6","article-title":"P-005: effectiveness of bridging therapy corresponds to improved outcomes after receiving CAR-T therapy: phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma","volume":"24","author":"Anguille","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.08.005_bib0014","article-title":"Effectiveness of bridging therapy corresponds to improved outcomes after receiving CAR-T therapy: phase 3 CARTITUDE-4 study of patients with relapsed, lenalidomide-refractory multiple myeloma","author":"Anguille","year":"2024","journal-title":"Poster Presented at: 21st International Myeloma Society (IMS) Annual Meeting"},{"key":"10.1016\/j.clml.2025.08.005_bib0015","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood.2024024582","article-title":"Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.08.005_bib0016","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/S2152-2650(23)01626-9","article-title":"P008: Idecabtagene vicleucel (ide-cel) vs standard regimens in triple-class\u2013exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis in patients receiving bridging therapy","volume":"23","author":"Einsele","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.08.005_bib0017","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene vicleucel for relapsed\/refractory multiple myeloma: real-world experience from the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2025.08.005_bib0018","first-page":"1514","article-title":"Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed\/refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience","volume":"109","author":"Hashmi","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2025.08.005_bib0019","doi-asserted-by":"crossref","first-page":"790.e1","DOI":"10.1016\/j.jtct.2024.05.025","article-title":"Absolute lymphocyte count and outcomes of multiple myeloma patients treated with idecabtagene vicleucel: the US Myeloma Immunotherapy Consortium real-world experience","volume":"30","author":"Khouri","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2025.08.005_bib0020","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood.2024025945","article-title":"Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed\/refractory multiple myeloma","volume":"145","author":"Sidana","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.08.005_bib0021","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-024-01555-4","article-title":"Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel","volume":"17","author":"Zanwar","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2025.08.005_bib0022","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/jha2.1039","article-title":"Rapid high-dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma","volume":"5","author":"Marable","year":"2024","journal-title":"EJHaem"},{"key":"10.1016\/j.clml.2025.08.005_bib0023","doi-asserted-by":"crossref","first-page":"9","DOI":"10.46989\/001c.116261","article-title":"The evolving role of bridging therapy during CAR-T therapy","volume":"6","author":"Bhaskar","year":"2024","journal-title":"Clin Hematol Int"},{"key":"10.1016\/j.clml.2025.08.005_bib0024","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1158\/2643-3230.BCD-24-0118","article-title":"Bispecific antibodies as bridging to BCMA CAR-T cell therapy for relapsed\/refractory multiple myeloma","volume":"6","author":"Fandrei","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"10.1016\/j.clml.2025.08.005_bib0025","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41375-024-02482-6","article-title":"International Myeloma Working Group Immunotherapy Committee recommendation on sequencing immunotherapy for treatment of multiple myeloma","volume":"39","author":"Costa","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2025.08.005_bib0026","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/01.HS9.0000846344.56300.e1","article-title":"P866: Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed\/refractory multiple myeloma patients treated with idecabtagene vicleucel (Bb2121)","volume":"6","author":"Rytlewski","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2025.08.005_bib0027","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1182\/blood-2024-202017","article-title":"Talquetamab bridging: paving the way to B-cell maturation antigen (BCMA) CAR-T cell therapy in relapsed\/refractory multiple myeloma (RRMM)","volume":"144","author":"Dhakal","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.08.005_bib0028","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-022-01296-2","article-title":"Patient selection for CAR T or BiTE therapy in multiple myeloma: which treatment for each patient?","volume":"15","author":"Kegyes","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2025.08.005_bib0029","doi-asserted-by":"crossref","first-page":"504.e1","DOI":"10.1016\/j.jtct.2023.05.016","article-title":"Intensity of cyclophosphamide-based bridging therapy before chimeric antigen receptor T cell therapy in myeloma","volume":"29","author":"Zafar","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2025.08.005_bib0030","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1002\/cncr.32178","article-title":"Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: utility of re-treatment with daratumumab among refractory patients","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2025.08.005_bib0031","series-title":"Tandem Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR","article-title":"FREEDOMM: fifth-line or later real-world evaluation of efficacy and disease outcomes in multiple myeloma with ciltacabtagene autoleucel: treatment-free interval and overall survival with bridging therapies","author":"Ailawadhi","year":"2025"},{"key":"10.1016\/j.clml.2025.08.005_bib0032","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.clml.2021.10.013","article-title":"Comparison of cilta-cel, an anti-BCMA CAR-T cell therapy, versus conventional treatment in patients with relapsed\/refractory multiple myeloma","volume":"22","author":"Costa","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.08.005_bib0033","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/hon.3123","article-title":"Cyclophosphamide etoposide dexamethasone as salvage and bridging therapy in relapsed refractory and extramedullary multiple myeloma","volume":"41","author":"Kauer","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2025.08.005_bib0034","first-page":"384","article-title":"Efficacy of selinexor in relapsed\/refractory multiple myeloma (RRMM) patients with del17p and other high-risk abnormalities (a retrospective single-center study)","volume":"14","author":"Ehsan","year":"2024","journal-title":"Life (Basel)"},{"key":"10.1016\/j.clml.2025.08.005_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109933","article-title":"Radiation therapy as a bridging and salvage strategy in patients with relapsed or refractory multiple myeloma undergoing BCMA-targeted CAR T-cell therapy","volume":"189","author":"Ababneh","year":"2023","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.clml.2025.08.005_bib0036","doi-asserted-by":"crossref","first-page":"6580","DOI":"10.1158\/1078-0432.CCR-21-0308","article-title":"The safety of bridging radiation with anti-BCMA CAR T-cell therapy for multiple myeloma","volume":"27","author":"Manjunath","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2025.08.005_bib0037","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.2022015526","article-title":"Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2025.08.005_sbref0038","series-title":"Prescribing Information","year":"2024"},{"key":"10.1016\/j.clml.2025.08.005_sbref0039","series-title":"Prescribing Information","year":"2023"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502500268X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502500268X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T15:15:29Z","timestamp":1772896529000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502500268X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S215226502500268X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.08.005","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimizing Selection of Bridging Therapies Prior to CAR-T Therapy Administration for Multiple Myeloma: Clinical Pearls From an Expert Roundtable","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}